In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Fibrocell Science, Inc.

http://www.fibrocellscience.com

Latest From Fibrocell Science, Inc.

Baxter Reports $45M Boost From COVID-19 Demand In Q1

The COVID-19 pandemic has increased demand for products from all of Baxter’s businesses except its advanced surgery division. Overall, the diversified company’s global sales were up 8% in the first quarter.

Companies Commercial

Is Cardiometabolic Ripe For A Revival?

Opportunities in the cardiometabolic field are increasing, following a period of limited investment from larger biopharma players. Still, challenges remain, such as accessing funding at the earlier stages of development. 

Commercial Business Strategies

Finance Watch: iTeos, Pandion And Aspen Show COVID-19 Hasn’t Slowed VC Deals Yet

Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds. 

Financing Business Strategies

At Paragon, Jeffrey Aronin Has Launched His Next Act – Or Eight Of Them

Jeffrey Aronin, who presided over Marathon Pharmaceuticals during a drug-pricing kerfuffle that drew congressional scrutiny, has built a portfolio of new drug companies at Paragon Biosciences.

StartUps and SMEs Research and Development Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Isolagen, Inc.
UsernamePublicRestriction

Register